Skip to content

News

CloudTrade builds Exec Team

Tech Market View reported more good news from Calculus portfolio company CloudTrade, who have strengthened their exec team and board. The article featured in the publication’s ‘UK Hot Views’ section reported “just a few weeks ago, CloudTrade raised £2m to accelerate growth with the support of Great British Scaleup programme Advisory Sponsor, ScaleUp Group (see CloudTrade’s head in … Continued

Money Dashboard reaches 1 million milestone

Calculus Capital portfolio company, Money Dashboard, has reached an important milestone as the number of bank accounts connected to its app surpassed one million, driven by its 450,000 users. Edinburgh-based fintech Money Dashboard offers its users a free view of their finances (from bank accounts, credit cards, etc.) in one secure place. The company’s proprietary … Continued

Calculus VCT – Now Open for Subscription

Calculus Capital launches VCT fundraising – providing exposure to a diverse portfolio of entrepreneurial growth companies Calculus Capital has launched a £10 million fundraising for the Calculus VCT, which aims to deliver investors an annual dividend of 4.5% and capital growth. The proceeds from the fundraising will be used to invest in new companies and to … Continued

Cornerstone: The rise of subscription boxes

Oliver Bridge, Cornerstone CEO has recently been interviewed regarding the rise in subscription boxes and future plans for Cornerstone. To read the full article please click here. Cornerstone provides high quality British skincare products and German engineered razors to customers in the UK via an online subscription service. Founded in 2014 by entrepreneur and former … Continued

Calculus invests in Arecor

Calculus Capital has led a £6m funding round in Arecor, the UK-based biopharmaceutical formulation company, to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The funding also involved Albion Capital and Downing Ventures, with BioScience Managers Limited advising Downing Ventures. Through the application of its technology platform, Arecor is creating faster working, more … Continued

Chief Executive John Glencross featured on BBC Newsnight

John Glencross was asked by BBC Newsnight to comment on the position for investors during the ongoing Brexit negotiations. To watch the short clip please see below. [youtube id=”StTC1jD2Emc” align=”center” mode=”normal” autoplay=”no”]

Leo de Montaignac, CEO of Weedingtech: Public concern over chemical herbicides

Calculus Capital portfolio company CEO, Leo de Montaignac of Weedingtech writes for The Parliament Magazine around the use of glyphosate in public and urban spaces. The primary objective for their product Foamstream was to offer an effective, affordable commercial product as an alternative to traditional chemical herbicides like glyphosate, which could be used in public … Continued

Spotlight On: Blu Wireless Technology

As part of our ‘Spotlight On’ series, we focus on Blu Wireless Technology a technology company, developing semiconductor designs for the next generation of high speed wireless data transfer. Calculus Capital completed a £2.4m investment in Blu Wireless (‘BWT’) in June 2017, as the cornerstone investor in a £7.2 million institutional and private investment round in conjunction … Continued

Spotlight On: AnTech

As part of our ‘Spotlight On’ series, we focus on AnTech a specialist engineering company in the oil and gas industry. AnTech Limited has two different businesses: manufacturing products for use mainly in oil and gas production (as opposed to drilling) and providing directional coil drilling services. AnTech’s Products Division supplies high specification customised and standard products; … Continued

C4X awarded grant from the US National Institute on Drug Abuse (NIDA)

C4X recently announced that their C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an … Continued

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information